جمعه 6 تیر 1404
[Archive]
دوره ۳۱، شماره ۱۴۹ - ( ۱۰-۱۴۰۲ )
جلد ۳۱ شماره ۱۴۹ صفحات ۶۱۱-۶۰۲ |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Qais Ahmed M, A Razak Al-Sharifi Z, Gorial F. Serum Levels of Tripartite Motif-containing Protein 72 (TRIM72) in Iraqi Rheumatoid Arthritis Patients and Its Relevance to the Disease Activity State. J Adv Med Biomed Res 2023; 31 (149) :602-611
URL: http://journal.zums.ac.ir/article-1-7330-fa.html
URL: http://journal.zums.ac.ir/article-1-7330-fa.html
Serum Levels of Tripartite Motif-containing Protein ۷۲ (TRIM۷۲) in Iraqi Rheumatoid Arthritis Patients and Its Relevance to the Disease Activity State. Journal of Advances in Medical and Biomedical Research. ۱۴۰۲; ۳۱ (۱۴۹) :۶۰۲-۶۱۱
چکیده: (۱۷۱۳ مشاهده)
Background and Objective: Uncontrolled active rheumatoid arthritis patients have a progressive disability, pain, swelling problems, and stiffness that often lead to systemic complications, early death, socioeconomic costs, and comorbidity. The objectives of this study were to measure the serum levels of Tripartite motif-containing protein 72 in Iraqi patients with rheumatoid arthritis and healthy individuals, assessment of the efficiency of Tripartite motif-containing protein 72, determine their essential serum rates in association with disease activity, sociodemographic and clinical specifications of the diseases.
Materials and Methods: In this case-control study, 117 Iraqi patients with rheumatoid arthritis were investigated according to the 2010 American College of Rheumatology / European League Against Rheumatism from December 2020 to March 2022. The patients were divided into two groups. Group 1 were the RA patients with active disease, Group 2 were the RA patients with inactive disease, and healthy subjects served as the control group.
Results: Serum levels of Tripartite motif-containing protein 72 in the active RA groups (101.92±160.18 Pg/mL) were significantly higher as compared with the inactive RA group (64.58±54.34 Pg/mL) and the control group (41.06 ±32.48 Pg/mL) (P˂0.005). Tripartite motif-containing protein 72 could not discriminate between RA and the controls (since its AUC ≥0.689).
Conclusion: There was a positive relationship between DAS-28ESR and Tripartite motif-containing protein 72 levels, which induces bone erosion. The serum Tripartite motif-containing protein 72 level showed a significant elevation in rheumatoid arthritis patients compared with healthy controls. Tripartite motif-containing protein 72 had a poor discriminative ability between RA and the control group.
نوع مطالعه: مقاله پژوهشی |
موضوع مقاله:
Health Improvement Strategies
دریافت: 1402/6/27 | پذیرش: 1402/9/7 | انتشار: 1402/11/9
دریافت: 1402/6/27 | پذیرش: 1402/9/7 | انتشار: 1402/11/9
فهرست منابع
1. Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum. 2021;51(1):219-29. [DOI:10.1016/j.semarthrit.2020.11.005] [PMID]
2. Janke K, Biester K, Krause D, Richter B, Schürmann C, Hirsch K, et al. Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data. BMJ. 2020;370:m2288. [DOI:10.1136/bmj.m2288] [PMID] [PMCID]
3. Prothero L, Barley E, Galloway J, Georgopoulou S, Sturt J. The evidence base for psychological interventions for rheumatoid arthritis: a systematic review of reviews. Int J Nurs Stud. 2018;82:20-9. [DOI:10.1016/j.ijnurstu.2018.03.008] [PMID]
4. Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):1-8. [DOI:10.1186/s13075-019-1866-2] [PMID] [PMCID]
5. Meroni G, Diez-Roux G. TRIM/RBCC, a novel class of 'single protein RING finge r' E3 ubiquitin ligases. Bioessays. 2005;27(11):1147-57. [DOI:10.1002/bies.20304] [PMID]
6. Watanabe M, Hatakeyama S. TRIM proteins and diseases. J Biochem. 2017;161(2):135-44. [DOI:10.1093/jb/mvw087] [PMID]
7. Jones EL, Laidlaw SM, Dustin LB. TRIM21/Ro52-roles in innate immunity and autoimmune disease. Front Immunol. 2021;12:738473. [DOI:10.3389/fimmu.2021.738473] [PMID] [PMCID]
8. Liu J, Zhang C, Wang X, Hu W, Feng Z. Tumor suppressor p53 cross-talks with TRIM family proteins. Genes Dis. 2021;8(4):463-74. [DOI:10.1016/j.gendis.2020.07.003] [PMID] [PMCID]
9. Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer. 2011;11(11):792-804. [DOI:10.1038/nrc3139] [PMID]
10. Huang Y, Xiao Y, Zhang X, Huang X, Li Y. The emerging roles of tripartite motif proteins (TRIMs) in acute lung injury. J Immunol Res. 2021;2021:1-9. [DOI:10.1155/2021/1007126] [PMID] [PMCID]
11. Zhang JR, Li XX, Hu WN, Li CY. Emerging role of TRIM family proteins in cardiovascular disease. Cardiology. 2020;145(6):390-400. [DOI:10.1159/000506150] [PMID]
12. Bhaduri U, Merla G. Ubiquitination, biotech startups, and the future of TRIM family proteins: a TRIM-Endous opportunity. Cells. 2021;10(5):1015. [DOI:10.3390/cells10051015] [PMID] [PMCID]
13. Ozato K, Shin DM, Chang TH, Morse III HC. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 2008;8(11):849-60. [DOI:10.1038/nri2413] [PMID] [PMCID]
14. Park EY, Kwon OB, Jeong BC, Yi JS, Lee CS, Ko YG, et al. Crystal structure of PRY-SPRY domain of human TRIM72. Proteins Struct Funct Genet. 2010;78(3):790-5. [DOI:10.1002/prot.22647] [PMID]
15. Li Z, Wang L, Yue H, Whitson BA, Haggard E, Xu X, et al. MG53, a tissue repair protein with broad applications in regenerative medicine. Cells. 2021;10(1):122. [DOI:10.3390/cells10010122] [PMID] [PMCID]
16. Whitson BA, Tan T, Gong N, Zhu H, Ma J. Muscle multiorgan crosstalk with MG53 as a myokine for tissue repair and regeneration. Curr Opin Pharmacol. 2021;59:26-32. [DOI:10.1016/j.coph.2021.04.005] [PMID] [PMCID]
17. Ishiwata-Endo H, Kato J, Tonouchi A, Chung YW, Sun J, Stevens LA, et al. Role of a TRIM72 ADP-ribosylation cycle in myocardial injury and membrane repair. JCI insight. 2018;3(22):e97898. [DOI:10.1172/jci.insight.97898] [PMID] [PMCID]
18. Zhong W, Benissan-Messan DZ, Ma J, Cai C, Lee PH. Cardiac effects and clinical applications of MG53. Cell Biosci. 2021;11(115). [DOI:10.1186/s13578-021-00629-x] [PMID] [PMCID]
19. Wang Z, Li H, Wang H, Li X, Zhang Q, Wang H, et al. TRIM72 exerts antitumor effects in breast cancer and modulates lactate production and MCT4 promoter activity by interacting with PPP3CA. Anticancer Drugs. 2022;33(5):489. [DOI:10.1097/CAD.0000000000001304] [PMID] [PMCID]
20. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796-806. [DOI:10.1186/ar1740] [PMID] [PMCID]
21. Fransen J, Van Riel PL. The Disease Activity Score and the EULAR Response Criteria. Rheum Dis Clin. 2009;35(4):745-57. [DOI:10.1016/j.rdc.2009.10.001] [PMID]
22. Prevoo ML, Van'T Hof M, Kuper HH, Van Leeuwen MA, Van De Putte LB, Van Riel PL. Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8. [DOI:10.1002/art.1780380107] [PMID]
23. Yang SH, Gao CY, Li L, Chang C, Leung PS, Gershwin ME, et al. The molecular basis of immune regulation in autoimmunity. Clin Sci. 2018;132(1):43-67. [DOI:10.1042/CS20171154] [PMID]
24. Feng X, Xu X, Shi Y, Liu X, Liu H, Hou H, et al. Body mass index and the risk of rheumatoid arthritis: an updated dose-response meta-analysis. Biomed Res Int. 2019;2019:3579081. [DOI:10.1155/2019/3579081] [PMID] [PMCID]
25. Ren S, Bermejo I, Simpson E, Wong R, Scott DL, Young A, et al. Baricitinib for previously treated moderate or severe rheumatoid arthritis: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018;36:769-78. [DOI:10.1007/s40273-018-0616-7] [PMID] [PMCID]
26. Alpízar-Rodríguez D, Pluchino N, Canny G, Gabay C, Finckh A. The role of female hormonal factors in the development of rheumatoid arthritis. Rheumatology. 2017;56(8):1254-63. [DOI:10.1093/rheumatology/kew318] [PMID]
27. Romo-García MF, Zapata-Zuñiga M, Enciso-Moreno JA, Castañeda-Delgado JE. Chapter2: The Role of Estrogens in Rheumatoid Arthritis Physiopathology. In Rheumatoid Arthritis Other Perspect towards a Better Practice. 2020., London, U.K: Biritish Library.
28. Edens C, Antonelli M. Polycystic Ovarian Syndrome in Rheumatic Disease. In Arthritis & Rheumatology. 2017. Vol. 69. NJ, USA: Wiley.
29. Mollard E, Pedro S, Chakravarty E, Clowse M, Schumacher R, Michaud K. The impact of menopause on functional status in women with rheumatoid arthritis. Rheumatology. 2018;57(5):798-802. [DOI:10.1093/rheumatology/kex526] [PMID]
30. Serhal L, Lwin MN, Holroyd C, Edwards CJ. Rheumatoid arthritis in the elderly: Characteristics and treatment considerations. Autoimmun Rev. 2020;19(6):102528. [DOI:10.1016/j.autrev.2020.102528] [PMID]
31. Eun Y, Jeon KH, Han K, Kim D, Kim H, Lee J, et al. Menopausal factors and risk of seropositive rheumatoid arthritis in postmenopausal women: a nationwide cohort study of 1.36 million women. Sci Rep. 2020;10(1):20793. [DOI:10.1038/s41598-020-77841-1] [PMID] [PMCID]
32. Kaufman MB. Pre-Eclampsia Risk & Rheumatic Disease. 2022;(May2022). Available from: [https://www.the-rheumatologist.org/article/pre-eclampsia-risk-rheumatic-disease/]
33. Di Giuseppe D, Discacciati A, Orsini N, Wolk A. Cigarette smoking and risk of rheumatoid arthritis: a dose-response meta-analysis. Arthritis Res Ther. 2014;16(2):1-7. [DOI:10.1186/ar4498] [PMID] [PMCID]
34. Yin J, He D, Jiang L, Cheng F, Guo Q, Huang S, et al. Influence of cigarette smoking on rheumatoid arthritis risk in the Han Chinese population. Front Med. 2017;4:76. [DOI:10.3389/fmed.2017.00076] [PMID] [PMCID]
35. Hedström AK, Stawiarz L, Klareskog L, Alfredsson L. Smoking and susceptibility to rheumatoid arthritis in a Swedish population-based case-control study. Eur J Epidemiol. 2018;33:415-23. [DOI:10.1007/s10654-018-0360-5] [PMID] [PMCID]
36. Baecklund F, Foo JN, Askling J, Eloranta S, Glimelius I, Liu J, et al. Possible interaction between cigarette smoking and HLA-DRB1 variation in the risk of follicular lymphoma. Am J Epidemiol. 2017;185(8):681-7. [DOI:10.1093/aje/kww118] [PMID]
37. Hedström AK, Rönnelid J, Klareskog L, Alfredsson L. Complex relationships of smoking, HLA-DRB1 genes, and serologic profiles in patients with early rheumatoid arthritis: update from a Swedish Population-Based Case-Control study. Arthritis Rheumatol. 2019;71(9):1504-11. [DOI:10.1002/art.40852] [PMID] [PMCID]
38. Regueiro C, Rodriguez-Rodriguez L, Lopez-Mejias R, Nuño L, Triguero-Martinez A, Perez-Pampin E, et al. A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis. Sci Rep. 2020;10(1):3355. [DOI:10.1038/s41598-020-60305-x] [DOI:10.1038/s41598-020-75520-9]
39. Liu X, Tedeschi SK, Barbhaiya M, Leatherwood CL, Speyer CB, Lu B, et al. Impact and timing of smoking cessation on reducing risk of rheumatoid arthritis among women in the nurses' health studies. Arthritis Care Res. 2019;71(7):914-24. [DOI:10.1002/acr.23837] [PMID] [PMCID]
40. Zhang W, Lin H, Zou M, Yuan Q, Huang Z, Pan X, et al. Nicotine in inflammatory diseases: anti-inflammatory and pro-inflammatory effects. Front Immunol. 2022;13:826889. [DOI:10.3389/fimmu.2022.826889] [PMID] [PMCID]
41. Han X, Chen D, Liufu N, Ji F, Zeng Q, Yao W, et al. MG53 protects against sepsis-induced myocardial dysfunction by upregulating peroxisome proliferator-activated receptor-α. Oxid Med Cell Longev. 2020;2020. [DOI:10.1155/2020/7413693] [PMID] [PMCID]
42. Chen Z, Yin X, Li K, Chen S, Li H, Li Y, et al. Serum levels of TRIM72 are lower among patients with colon cancer: identification of a potential diagnostic marker. Tohoku J Exp Med. 2018;245(1):61-8. [DOI:10.1620/tjem.245.61] [PMID]
43. Liang T, Song M, Xu K, Guo C, Xu H, Zhang H, et al. TRIM32 promotes inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes. Scand J Immunol. 2020;91(6):e12876. [DOI:10.1111/sji.12876] [PMID]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
